BBHC
PTGX icon

Brown Brothers Harriman & Co’s Protagonist Therapeutics PTGX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93K Hold
81
– – ﹤0.01% 1428
2026
Q1 		$8.54K Hold
81
– – ﹤0.01% 1385
2025
Q4 		$7.08K Hold
81
– – ﹤0.01% 1422
2025
Q3 		$5.38K Hold
81
– – ﹤0.01% 1396
2025
Q2 		$4.48K Buy
+81
New +$3.89K ﹤0.01% 1286

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Brown Brothers Harriman & Co's PTGX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its Protagonist Therapeutics (PTGX) position steady in Q2 2026 at 81 shares worth $9.93K. The position accounts for ﹤0.01% of the portfolio, ranked #1428.

Brown Brothers Harriman & Co first reported a position in PTGX in Q2 2025 and has held it in 5 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Brown Brothers Harriman & Co held 81 shares of Protagonist Therapeutics worth $9.93K as of Q2 2026.
  • Brown Brothers Harriman & Co left its Protagonist Therapeutics share count unchanged in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1428 holding.
  • Brown Brothers Harriman & Co first reported a position in Protagonist Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.